Medical device giant Boston Scientific added to its string of recent acquisitions by announcing its plan to buy Axonics, a maker of neurostimulation devices that treat urinary and bowel dysfunction, for $3.7 billion. Experts agree that this deal will make a profitable impact on Boston Scientific’s urology business.
Roughly 100 million people in the U.S. and Europe are challenged with having an overactive bladder and 40 million with fecal control issues. An implant that stimulates the sacral nerves in the pelvis is a new option for treatment.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
SoCal startup Axonics Modulation Technologies has raised $17.3 million, according to a new regulatory filing. Based in Irvine, the startup is developing implantable sacral neuromodulation devices that treat conditions like overactive bladder and fecal incontinence. A representative for Axonics said that it’s not yet speaking publicly about this financing. Just last year, it raised an […]